Syrma vs Kaynes: Which EMS Stock Has the Better Growth Potential?
Syrma is being valued as a high-growth EMS company that has consistently delivered strong earnings growth. Kaynes, meanwhile, trades at a lower multiple despite making large investments in PCB manufacturing and semiconductor assembly. That difference matters because both companies are expected to grow rapidly. The question is not simply whether Syrma is growing faster. It is whether that additional growth is large enough to justify the substantially higher multiple. On Wednesday, Syrma is at around Rs.1,750.80, with a market capitalisation of approximately Rs.33,760.76 crore and a trailing P/E of 81.28x. Kaynes traded at around Rs.3,557, with a market capitalisation of approximately Rs.23,891.15 crore and a trailing P/E of 68.1x. In other words, investors are currently paying roughly Rs.13.18 more for each rupee of trailing earnings generated by Syrma than by Kaynes .
Syrma's Earnings Growth Is Strong, But the Multiple Already Reflects It
Syrma has delivered a sharp acceleration in earnings, giving investors a fundamental reason to assign it a premium. In Q1 FY27, revenue increased 68.3% year on year to Rs.1,588.6 crore, while profit before tax increased 109.7% to Rs.140.8 crore. PAT also went up 101% to Rs.106 crore. Revenue also rose 8.4% sequentially, suggesting that the quarter was not simply benefiting from a weak base.
Also Read: 5 Stocks That Could Benefit From Karnataka Government’s ₹1,300 Crore Data Centre Push
The FY26 numbers reinforce the earnings trajectory. Syrma reported consolidated revenue of Rs.4,856.9 crore, up 27% year on year. EBITDA increased 56% to Rs.582.3 crore, while PAT increased 87% to Rs.345.8 crore. Export revenue grew 41% during the year and crossed Rs.1,200 crore.
That creates a strong fundamental case for the current valuation. The problem is that a P/E of around 81x means the market is already pricing in a substantial amount of this growth. JPMorgan's latest estimates put Syrma's FY26–FY28 revenue CAGR at 37% and EPS CAGR at 34%, with FY28E ROCE at 21%. Even after allowing for that growth, the brokerage calculates that Syrma trades at approximately 56.6x FY28 estimated earnings.
That distinction is important. A 81x trailing P/E can fall quickly if earnings grow at 30% or more, but that does not automatically make the stock inexpensive. At 56.6x FY28 earnings, the valuation would still represent a substantial premium to traditional manufacturing businesses. The market therefore needs Syrma to deliver not just high growth, but high growth that remains durable for several years.
Kaynes Starts From a Lower Valuation Base
Kaynes enters the comparison with a different earnings profile. In Q1 FY27, revenue increased 40.5% year on year to Rs.946 crore, but net profit declined 24.4% to Rs.56.4 crore. Revenue also fell 23.9% sequentially from Q4 FY26.
That earnings decline explains part of the valuation gap. Investors are currently paying approximately 68x trailing earnings for Kaynes, compared with roughly 81x for Syrma. Kaynes therefore trades at a significantly lower earnings multiple despite remaining a high-growth EMS company.
The forward valuation is also lower. Kaynes is trading at roughly 59x forward earnings, compared with its trailing multiple of about 68x. The market is effectively pricing Kaynes as a company whose earnings need to recover as its new investments begin contributing. That creates a different setup from Syrma.
Syrma's valuation depends heavily on continued strong execution. Kaynes' valuation depends more heavily on whether its large investments translate into a materially larger earnings base.
The Growth Premium Needs to Be Measured Against the Earnings Premium
Syrma's biggest argument for its premium is growth. JPMorgan expects Syrma to deliver a 37% revenue CAGR between FY26 and FY28, compared with 34% EPS CAGR. The brokerage expects EBITDA margins to remain around 10.5% to 10.7% through FY27–FY29.
Kaynes also has substantial growth expectations embedded in its valuation. Jefferies expects Kaynes' sales to grow at around 30% CAGR between FY26 and FY29, while S&P Global's Visible Alpha consensus earlier projected revenue increasing from approximately Rs.3,840 crore in FY26 to Rs.5,810 crore in FY27 as OSAT and PCB operations begin contributing.
This creates an interesting valuation comparison. Syrma's projected revenue CAGR is around seven percentage points higher than the 30% growth expected for Kaynes by Jefferies. But Syrma's current trailing P/E is roughly 1.19x higher.
Also Read: 5 Fundamentally Strong Stocks to Buy Now, Trading at a Discount of Up to 43%
The difference becomes clearer when looking at valuation relative to growth. Syrma's approximately 81x trailing P/E is about 2.39 times its 34% projected FY26–FY28 EPS CAGR. Kaynes' approximately 68x trailing P/E is about 2.27 times the roughly 30% sales CAGR expected through FY29.
These are not directly comparable metrics because one uses EPS growth and the other uses revenue growth. Still, they illustrate how much more aggressively Syrma is being priced. The key question is therefore whether Syrma's superior growth can remain sufficiently persistent to offset its higher starting multiple.
Syrma Has Better Recent Earnings Visibility
One reason the market may be willing to pay more for Syrma is its recent earnings delivery. In Q1 FY27, Syrma increased revenue by 68.3% and PBT by 109.7%. Kaynes, by comparison, increased revenue by 40.5% but reported a 24.4% decline in net profit.
Syrma also generated positive operating cash flow during FY26 while reducing net working capital days. Revenue increased 27%, EBITDA increased 56% and PAT increased 87%.
Kaynes is in a different phase because its capital expenditure is currently weighing on cash generation and earnings. During Q1 FY27, operating cash flow was negative Rs.259 crore, although this improved from negative Rs.379 crore a year earlier. Its order book nevertheless increased 20.3% to approximately Rs.8,900 crore.
This creates an important distinction for the valuation. Syrma's premium is supported by earnings that are already visible in reported financial statements. Kaynes' lower multiple is partly associated with earnings that investors expect to improve as new capacity comes online.
The Bigger Valuation Catalyst for Kaynes Is Its New Capacity
Kaynes is making a much larger capital-allocation bet relative to its existing business. The company has invested approximately Rs.1,200 crore in its OSAT and PCB operations and plans to invest another Rs.850 crore across FY27 and FY28. Both businesses are expected to start making a meaningful contribution from FY27.
S&P Global's Visible Alpha consensus estimates show the potential scale of this expansion. OSAT revenue is projected to rise from approximately Rs.72.7 crore in FY26 to Rs.570 crore in FY27, while PCB revenue is expected to start at around Rs.350 crore in FY27.
By FY30, OSAT revenue is projected at approximately Rs.2,560 crore and PCB revenue at about Rs.1,960 crore. That could materially change Kaynes' earnings base. The company reported FY26 revenue of approximately Rs.3,783 crore, so the projected OSAT and PCB businesses could become significant relative to its existing operations if these forecasts are achieved.
But the same investment also creates execution risk. Semiconductor packaging and PCB manufacturing have different capital requirements, qualification cycles and depreciation profiles from conventional EMS operations. Kaynes therefore needs the new capacity to reach sufficient utilisation before the investment can translate into higher returns on capital. That is why a lower P/E does not automatically mean a lower-risk valuation.
Syrma Also Has a Component Expansion, But at a Different Scale
Syrma is also moving beyond conventional EMS into components, particularly multilayer PCBs. Its planned PCB project involves approximately Rs.800 crore of phased investment, with the first phase around Rs.400 crore. The company is targeting new capabilities while continuing to expand its existing electronics manufacturing operations.
This gives Syrma another potential source of growth without requiring the market to completely revalue the company around a new business model. The difference is therefore largely one of capital intensity and starting valuation.
Syrma is already valued at approximately 81x trailing earnings, so successful PCB expansion would reinforce an already expensive growth narrative. Kaynes trades at approximately 68x trailing earnings, meaning successful OSAT and PCB execution could potentially change the earnings base against which its current multiple is calculated.
What Would Justify Syrma's Premium?
For Syrma's current valuation to remain supported, earnings need to grow rapidly enough for the P/E to compress even if the share price remains stable or rises only moderately. JPMorgan's FY28 estimate of 56.6x earnings provides a useful benchmark. If Syrma reaches the projected earnings level, the valuation would fall materially from today's 81x trailing P/E, but it would still remain above 50x earnings.
Jefferies' earlier valuation work was even more conservative, using a 50x FY28E EPS multiple for Syrma. That difference illustrates how sensitive the investment case is to the multiple investors are willing to assign.
If the market continues to value Syrma at a premium because of its growth, the stock can sustain a high valuation even with strong earnings growth. If investors eventually apply a lower manufacturing multiple, earnings would have to grow substantially just to offset the resulting multiple compression. This is the central risk in the Syrma case: earnings can grow strongly while shareholder returns remain increasingly dependent on the valuation multiple.
What Would Re-rate Kaynes?
Kaynes has almost the opposite setup. Its trailing valuation is already below Syrma's, but near-term earnings have been affected by investment and execution costs. The re-rating case therefore depends on converting its order book and new capacity into earnings. The company had an order book of approximately Rs.8,900 crore in Q1 FY27, compared with Syrma's approximately Rs.6,600 crore. Order-book size alone, however, does not determine future profitability.
If OSAT and PCB operations begin contributing meaningfully from FY27, revenue growth could accelerate while the current earnings base expands. That would reduce the effective P/E without requiring a higher share price.
The opposite scenario matters just as much. If capacity utilisation takes longer than expected, depreciation and operating costs could remain elevated while revenue contribution stays modest. In that case, the apparently lower P/E could remain elevated because earnings would not expand as projected.
The Valuation Question Is More Important Than the Growth Question
Both companies have credible structural growth opportunities, but they are entering that opportunity from very different valuation starting points. Syrma combines stronger recent execution with a much higher valuation. Its Q1 FY27 revenue grew 68.3% and PBT increased 109.7%, while JPMorgan expects 34% EPS CAGR through FY28. Yet the stock still trades at approximately 81x trailing earnings and 56.6x JPMorgan's FY28 estimate.
Kaynes combines weaker recent profit performance with a lower valuation. Its Q1 FY27 revenue increased 40.5%, but net profit declined 24.4%, while its trailing P/E is around 68x and forward P/E is approximately 59x.
Also Read: 5 Stocks to Watch as India’s Battery Storage Capacity to Surge From 1 GWh to 50 GWh in 2 years
The investment thesis therefore comes down to how much of the future each valuation already discounts. Syrma needs sustained high earnings growth to support a premium that is already visible in its multiple. Kaynes needs successful execution of its OSAT and PCB investments for its current valuation to translate into a substantially larger earnings base.
The most important variables from here are therefore not simply revenue growth. Investors need to watch EPS growth relative to the P/E paid, margin progression, ROCE after new capacity comes online, working-capital requirements and the pace at which PCB and semiconductor investments begin contributing to earnings.
In an EMS industry where both companies are pursuing substantial capacity expansion, the key question is not simply which company can grow faster. It is how much of that growth is already embedded in today's share price.